ChemicalBook >> CAS DataBase List >>Brontictuzumab

Brontictuzumab

CAS No.
1447814-75-6
Chemical Name:
Brontictuzumab
Synonyms
Brontictuzumab;Brontictuzumab (anti-NOTCH1);Research Grade Brontictuzumab;Research Grade Brontictuzumab(DHE48301)
CBNumber:
CB08080903
Molecular Formula:
Molecular Weight:
0
MDL Number:
MOL File:
Mol file
MSDS File:
SDS
Last updated:2026-04-24 14:58:52

Brontictuzumab Properties

form Liquid
color Colorless to light yellow
FDA UNII UNY2TQA40E
NCI Drug Dictionary brontictuzumab

Brontictuzumab price

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
ChemScene CS-0620827 Brontictuzumab 95.00% 1447814-75-6 1mg $487 2026-06-04 Buy
ChemScene CS-0620827 Brontictuzumab 95.00% 1447814-75-6 5mg $1267 2026-06-04 Buy
ChemScene CS-0620827 Brontictuzumab 95.00% 1447814-75-6 10mg $2026 2026-06-04 Buy
aablocks AA029YCP Brontictuzumab ≥95%(SDS-PAGE&SEC-HPLC) 1447814-75-6 1mg $770 2026-06-02 Buy
aablocks AA029YCP Brontictuzumab ≥95%(SDS-PAGE&SEC-HPLC) 1447814-75-6 5mg $2000 2026-06-02 Buy
Product number Packaging Price Buy
CS-0620827 1mg $487 Buy
CS-0620827 5mg $1267 Buy
CS-0620827 10mg $2026 Buy
AA029YCP 1mg $770 Buy
AA029YCP 5mg $2000 Buy

Brontictuzumab Chemical Properties,Uses,Production

Uses

Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma[1][2][3].

in vivo

Brontictuzumab (15 mg/kg, i.p.) reduces tumor burden in T-ALL xenograft[3].
Brontictuzumab (20 mg/kg, i.p., every 4days) inhibits DLL4 induced activation of Notch1 in MCL model[2].

Animal Model:T-ALL xenograft[3]
Dosage:15 mg/kg
Administration:Intraperitoneal injection (i.p.), twice weekly.
Result:Inhibited tumor growth and reduced the size of the spleen.
Showed massive infiltration and replacement of normal hematopoiesis by leukemia cells.
Animal Model:NSG mice injected with DLL4-stimulated NOTCH1-mutated mino cells ex vivo[2]
Dosage:20 mg/kg
Administration:Intraperitoneal injection (i.p.)
Result:Inhibited cleaved Notch1 but was not enough to cause a significant efficacy in tumor growth.

References

[1] Ferrarotto R, et al. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol. 2018 Jul 1;29(7):1561-1568. DOI:10.1093/annonc/mdy171
[2] Silkenstedt E, et al. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy. J Exp Clin Cancer Res. 2019 Nov 1;38(1):446. DOI:10.1186/s13046-019-1458-7
[3] Agnusdei V, et al. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. Leukemia. 2014 Feb;28(2):278-88. DOI:10.1038/leu.2013.183

Brontictuzumab Preparation Products And Raw materials

Raw materials

Preparation Products

Brontictuzumab Suppliers

Global( 19)Suppliers
Supplier Tel Email Country ProdList Advantage
Shanghai YuanYe Biotechnology Co., Ltd. 15026964105 2881489226@qq.com China 89667 60
ShangHai Biochempartner Co.,Ltd 177-54423994 17754423994 2853530910@QQ.com China 8000 62
Guangzhou Hongyuan Chemical Co.,Ltd 15817493340 981810490@qq.com China 1577 58
Wuhan Chemstan Biotechnology Co., Ltd. 027-65317797 15926423062 422450190@qq.com China 10305 58
Beijing Jin Ming Biotechnology Co., Ltd. 010-60605840 psaitong@jm-bio.com China 27626 58
TargetMol Chemicals Inc. 4008200310 15002144251 marketing@tsbiochem.com China 24951 58
Biolab Reagents 027-65279366 18108604356 products@biolabreagent.com China 9864 58
Wuhan Jingkangen Biomedical Technology Co., Ltd 13720134139 086-15871494362 13720134139 orders@jknbiochem.com China 7283 58
Shanghai Yifei Biotechnology Co. , Ltd. 021-65675885 18964387627 customer_service@efebio.com China 11963 58
Wuhan Acumen Bio-Technology Co.,ltd 027-027-16602739303 16602739303 673003916@qq.com China 4593 58
Brontictuzumab Research Grade Brontictuzumab(DHE48301) Research Grade Brontictuzumab Brontictuzumab (anti-NOTCH1) 1447814-75-6